タジマ　ヒロユキ   TAJIMA Hiroyuki   田島　廣之    所属   埼玉医科大学  医学部 国際医療センター　放射線科（放射線腫瘍科、画像診断、核医学科）    職種   特任教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events
掲載誌名	正式名：ACTA RADIOLOGICA ISSNコード：02841851
出版社	SAGE PUBLICATIONS LTD
巻・号・頁	55(7),793-801頁
著者・共著者	Satoru Murata,Shiro Onozawa,Chol Kim,Hiroyuki Tajima,Ryoji Kimata,Eiji Uchida,Shin-ichiro Kumita
発行年月	2014/09
概要	Background: Drug leakage and lack of a drug-removal system have prevented clinical application of isolated pelvic perfusion (IPP). These barriers were overcome with negative-balance IPP (NIPP) in experimental pig models. Here, a phase 1 clinical study of NIPP was performed in patients with incurable symptomatic rectal cancer.Purpose: To establish a safe regimen of high-dose regional chemotherapy with NIPP using cisplatin in patients with incurable rectal cancer.Material and Methods: Between June 2004 and January 2007, NIPP therapy was performed for 23 patients (11 women, 12 men; mean age, 58 years). NIPP was routinely performed twice over a 4-week interval. Dose-limiting toxicities (DLTs) were defined using a 5+3 design, and cisplatin doses were escalated from 170 mg/m(2), with a fixed 5-fluorouracil dose of 1000 mg/m(2). The grade of adverse events (AEs) at the first and second sessions of NIPP therapy, pharmacokinetics, and antitumor response were evaluated.Results: No DLTs were observed during the first session of NIPP. However, at the second session, two patients experienced the DLT of neuropathy after administration of 200 mg/m(2) cisplatin. Therefore, 190 mg/m(2) cisplatin
DOI	10.1177/0284185113507253